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Exome-wide association analysis reveals novel
coding sequence variants associated with lipid
traits in Chinese
Clara S. Tang1,*, He Zhang2,*, Chloe Y.Y. Cheung3,*, Ming Xu4,*, Jenny C.Y. Ho3, Wei Zhou2,5, Stacey S. Cherny1,6,7,
Yan Zhang8, Oddgeir Holmen9,10, Ka-Wing Au3, Haiyi Yu4, Lin Xu11, Jia Jia8, Robert M. Porsch1, Lijie Sun4, Weixian Xu4,
Huiping Zheng4, Lai-Yung Wong3, Yiming Mu12, Jingtao Dou12, Carol H.Y. Fong3, Shuyu Wang13, Xueyu Hong3,
Liguang Dong14, Yanhua Liao14, Jiansong Wang14, Levina S.M. Lam6, Xi Su15, Hua Yan15, Min-Lee Yang2, Jin Chen2,
Chung-Wah Siu3,16, Gaoqiang Xie17, Yu-Cho Woo3, Yangfeng Wu18, Kathryn C.B. Tan3,16, Kristian Hveem9,
Bernard M.Y. Cheung3,16,19, Sebastian Zo¨llner20, Aimin Xu3,16,19,21, Y. Eugene Chen2, Chao Qiang Jiang22, Youyi Zhang23,
Tai-Hing Lam11, Santhi K. Ganesh2,24, Yong Huo8, Pak C. Sham1,6,7,**, Karen S.L. Lam3,16,19,**, Cristen J. Willer2,5,24,**,
Hung-Fat Tse3,16,25,** & Wei Gao26,**
Blood lipids are important risk factors for coronary artery disease (CAD). Here we perform an
exome-wide association study by genotyping 12,685 Chinese, using a custom Illumina Huma-
nExome BeadChip, to identify additional loci inﬂuencing lipid levels. Single-variant association
analysis on 65,671 single nucleotide polymorphisms reveals 19 loci associated with lipids at
exome-wide signiﬁcance (Po2.69 10 7), including three Asian-speciﬁc coding variants in
known genes (CETP p.Asp459Gly, PCSK9 p.Arg93Cys and LDLR p.Arg257Trp). Furthermore,
missense variants at two novel loci—PNPLA3 p.Ile148Met and PKD1L3 p.Thr429Ser—also inﬂuence
levels of triglycerides and low-density lipoprotein cholesterol, respectively. Another novel gene,
TEAD2, is found to be associated with high-density lipoprotein cholesterol through gene-based
association analysis. Most of these newly identiﬁed coding variants show suggestive association
(Po0.05) with CAD. These ﬁndings demonstrate that exome-wide genotyping on samples of
non-European ancestry can identify additional population-speciﬁc possible causal variants,
shedding light on novel lipid biology and CAD.
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D
yslipidemia, often deﬁned as elevated levels of total
cholesterol (TC), triglyceride (TG) or low-density
lipoprotein cholesterol (LDL-C) or decreased level of
high-density lipoprotein cholesterol (HDL-C), is an important
risk factor for coronary artery disease (CAD)1 which is a major
cause of mortality and morbidity worldwide2. The incidence of
CAD and the prevalence of its major risk factors, such as
dyslipidemia, vary widely according to geographical location and
ethnicity3. Such differences could be due to environmental
factors, like smoking and diet, or underlying population genetic
differences. Mapping of the genetic loci affecting blood lipid levels
may shed light on disease pathogenesis and provide
pharmaceutical targets for prevention and treatment of CAD.
Recently, a multi-ethnic meta-analysis of genome-wide
association studies (GWAS) on 4188K individuals, the majority
being of European ancestry, discovered a total of 157 loci
associated with blood lipid levels that together accounted for
about 20–30% of the total genetic contribution4. Most of these
variants are common, non-coding, and with modest impact on
lipid levels, although rare coding variants with larger effects have
been identiﬁed in a number of genes, including PCSK9 (refs 5,6),
LDLR5,7, APOC3 (refs 8,9) and APOB4,6,10. By exploiting the
differences in linkage disequilibrium (LD) of the non-European
populations (2–9K), the study further narrowed down association
signals at ﬁve loci, corroborating ﬁndings of ﬁne-mapping
analyses on Europeans with a much larger sample size.
The vast majority of discovery efforts have been made in
samples of European ancestry4,6,11, which contain only a subset of
human genetic variation12. The degree of overlap between the
variants and genes that contribute to lipid heritability in different
populations is largely unexplored. During evolutionary history,
genetic drift and evolutionary selection have led to different
genetic architectures for populations in different geographic
areas13. For example, variants in APOC3 demonstrate higher
frequencies in isolated populations with different ancestry,
notably Greeks14 and Amish15. Furthermore, loss-of-function
mutations in PCSK9 are more prevalent in individuals
with African ancestry5,6. Inter-population differences in
allele frequencies may therefore affect the detectability of risk
variants16. This highlights the importance of association analyses
on non-European populations to identify novel loci inﬂuencing
lipid levels.
To systematically evaluate the contribution of coding variants
to lipid levels in an Asian population, we perform an exome-wide
association analysis using a custom Asian Exomechip17 on 12,685
individuals selected from 2 Chinese cohorts, the University of
Hong Kong Theme-based Research Scheme (HKU-TRS,
N¼ 5,233) and Peking University Health Science Center and
the University of Michigan Medical School study of Myocardial
Infarction (PUUMA-MI, N¼ 7,452). First, we address whether
known lipid variants identiﬁed in Europeans are associated with
blood lipid levels in East Asian samples. Then we compare the
effect size and power in detecting known variants between
HKU-TRS and a Norwegian study of similar sample size
(Nord-Trøndelag Health Study (HUNT) study, N¼ 5,643).
Next, we seek to identify coding variants in known loci
that may point to the functional lipid genes and explore
other protein-altering variants for novel lipid-associated
genes in this Asian population. We discover a total of
three Asian-speciﬁc associations involving rare nonsynonymous
changes and identify three novel lipid-associated loci
not previously reported. Our study demonstrates the
importance of ancestry-speciﬁc association analysis to discover
population-speciﬁc associations of rare variants and, most
importantly, to provide new insights into novel biological
pathways for lipid metabolism.
Results
Using an exome array augmented with custom markers,
we successfully genotyped 145,276 polymorphic single
nucleotide polymorphisms (SNPs) in 12,685 Chinese individuals
(Supplementary Table 1). Single-variant and gene-based
association analyses were carried out with respect to the four
blood lipid levels (LDL-C, HDL-C, TC and TG). Single-variant
score test statistics were presented for the following analyses,
unless stated otherwise. Speciﬁcally, we assessed association
of 65,671 variants that were polymorphic in both Chinese
cohorts and had at least 20 minor alleles (MACZ20). Of
these variants, 58% altered protein composition and 26% were
Asian-speciﬁc variants with minor allele frequency (MAF) o5%
(Supplementary Table 2).
Power and effect size comparison with HUNT-MI. We initially
examined the known European-identiﬁed GWAS variants4,11 in
our combined data set (N¼ 12,685). Of the 157 index SNPs, 123
variants, including 4 with MACo20, were successfully
genotyped. We then tested 119 variants for association
with their primary lipid traits. The analysis identiﬁed 8 variants
reaching genome-wide signiﬁcance (Po5 10 8) and 52
reaching nominal signiﬁcance (Po0.05). The large proportions
of associated variants were substantially more than
expected under the null hypothesis of no association (binomial
test P¼ 3.1 10 47 and P¼ 1.5 10 35, respectively;
Supplementary Table 3). Approximately 83% of the variants
(N¼ 99) had direction of effect concordant to those reported
(Supplementary Fig. 1).
To explore if differences in LD may affect power for detecting
association of the known GWAS SNPs in Asian samples, we
compared the number of signiﬁcant variants discovered in a
Norwegian cohort—HUNT-MI (N¼ 5,643)18—against one of
our Chinese cohorts—HKU-TRS (N¼ 5,233)—of similar sample
size. Compared with HUNT-MI, fewer signiﬁcant associations
were detected in HKU-TRS (4 versus 7 for genome-wide
signiﬁcant variants and 32 versus 45 for variants with binomial
test Po0.05; Supplementary Table 4), suggesting a slight decrease
in power to detect known European-identiﬁed variants in Asian
samples. Such differences might be due to LD differences between
the index SNP and the true causal variant. This hypothesis was
supported by a weaker correlation with the reported effect sizes
for Chinese at three of the four lipid traits (HKU-TRS: LDL-C
r2¼ 0.49, HDL-C r2¼ 0.61, TC r2¼ 0.13 and TG r2¼ 0.62) than
Norwegian (HUNT-MI: LDL-C r2¼ 0.46, HDL-C r2¼ 0.75, TC
r2¼ 0.47 and TG r2¼ 0.84).
Reﬁning association signals at known loci. Differences in LD
patterns, on the one hand, may affect the detectability of variants
tagging the casual SNP; on the other hand, it may help pinpoint
the causal variant. We next investigated if variants other than the
index SNPs could account for the association of the previously
established loci, with the caveat that the majority of the variants
we tested are coding. Including the eight loci with signiﬁcant
GWAS SNPs, a total of 16 known loci were associated with at
least 1 lipid trait at exome-wide signiﬁcance (Po2.69 10 7)
(Supplementary Figs 2–6; Supplementary Tables 5–8). The
association was evaluated after conditioning on nearby index
SNP(s), and vice versa, revealing that only signals of four loci
(ABCA1 for HDL-C, DOCK7-ANGPTL3, GCKR and MLXIPL for
TG) could be completely explained by the GWAS index
SNPs (Supplementary Data 1). This list could be further
extended to include LIPC if variants reported to show
independent associations were considered as well18.
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One of our non-index lead SNPs, rs13702 at the 30 untranslated
region of LPL, exhibited stronger association with HDL-C
(P¼ 1.3 10 18) than the GWAS SNP (rs12678919, r2¼ 0.47,
P¼ 5.7 10 15). Association of the GWAS SNP was largely
attenuated (conditional P¼ 4.0 10 3) once accounted for the
effect of rs13702, whereas rs13702 still showed near exome-wide
signiﬁcant association after conditional analysis (conditional
P¼ 7.2 10 7). This suggested that the LPL index SNP might
act as a proxy for rs13702. Reﬁnement of association signals by
population differences in LD could be further demonstrated by
our lead SNPs at CELSR2-SORT1 for LDL-C (rs12740374, P¼ 4.9
 10 18) and APOA5 for TG (rs651821, P¼ 5.0 10 102),
where both SNPs were highlighted as the new lead SNPs in
previous ﬁne-mapping analyses involving African and East Asian
populations, respectively4. Likewise, our lead SNP encoding
TM6SF2 p.Glu167Lys (rs58542926, P¼ 1.5 10 8) was recently
shown to be a causal variant altering TC and TG levels18,19.
New lead SNPs at APOB and DOCK6. Besides reﬁning known
signals, some of the new lead SNPs appeared largely independent
of the index SNPs (r2o0.03), representing novel associations not
previously reported (Table 1). At APOB, the new lead SNP
corresponded to a novel missense variant (rs13306194, encoding
p.Arg532Trp) associated with decreasing LDL-C (b¼  0.134 s.d.,
P¼ 1.2 10 12) and TC levels (b¼  0.129, P¼ 6.0 10 12),
whereas the GWAS index SNP was only weakly associated with
both lipid traits (P44 10 3). Interestingly, although APOB
p.Arg532Trp is relatively common among Asians (MAF¼ 0.13), it
has been found to be extremely rare in 1000 Genomes European
(MAF¼ 0.003) and African samples (MAF¼ 0.004), as well as
in HUNT-MI Norwegians (MAF¼ 7 10 4). Similarly, a
synonymous DOCK6 variant (rs737337, encoding p.Thr712Thr,
MAF¼ 0.27), known to be associated with HDL-C, was associated
with TC level (P¼ 7.5 10 10) in our study and displayed a large
difference in allele frequency across populations (MAF¼ 0.07 in
Europeans). Only marginal association has hitherto been reported
with TC.
Complex association at APOE and APOA5. For two of the
previously implicated loci, Apolipoprotein E (APOE) and APOA5,
we observed not only one but multiple independent association
signals. In some cases, a different lead SNP was observed for
different lipid traits. APOE, located in the apolipoprotein
family gene cluster (APOE–APOC1–APOC2–APOC4), showed
signiﬁcant association with all lipid traits under study. Stepwise
conditional analysis revealed two exome-wide signiﬁcant
independent associations with HDL-C, including an intronic lead
SNP (rs769449, MAF¼ 0.08, P¼ 3.8 10 10) and a known
independent SNP encoding APOC4 p.Leu96Arg (rs5167,
MAF¼ 0.45, P¼ 1.6 10 7) (Supplementary Fig. 7). The
intronic lead SNP is in moderately strong LD with the index SNP
(rs4420638, r2¼ 0.68, P¼ 0.002), whereas APOC4 p.Leu96Arg is
not linked to either SNP in the joint regression model
(all r2o6 10 4). For other lipid traits, a different lead
SNP (rs445925), also a known independent SNP associated with
LDL-C, was observed (PLDL-C¼ 1.9 10 64, PTC¼ 4.1 10 26,
PTG¼ 7.1 10 9). For all except TG, the associations were
signiﬁcantly independent, though the effects were largely reduced
after conditioning on the reported SNPs.
For the APOA5 locus, as mentioned previously, the strongest
association signal for TG and HDL-C mapped to the GWAS
ﬁne-mapped SNP (rs651821, or a proxy SNP for HDL-C
(rs662799, r2¼ 0.99))4 (Supplementary Figs 8 and 9). The
secondary association signal for HDL-C was originally masked
(rs10466588; unconditional P¼ 2.9 10 4 to conditional
P¼ 5.8 10 11) by the strong effect of the index SNPs,
but was later discovered through stepwise conditional analysis.
By further conditioning on rs10466588, we identiﬁed the
second independent signal in the region, which encodes
APOA5 p.Gly185Cys (rs2075291; unconditional b¼  0.3,
P¼ 1.2 10 29 to conditional b¼  0.38, P¼ 1.9 10 7).
This missense change is near Asian-speciﬁc with MAF of B6%,
but is present in low frequency in Africans (MAF¼ 0.2%) and not
observed in Europeans.
Asian-speciﬁc association at CETP, LDLR and PCSK9. In
addition, we also identiﬁed signiﬁcant association of three
Asian-speciﬁc missense variants deﬁned as being polymorphic in
Asian but monomorphic in other populations (Table 1). This
included a low-frequency missense CETP SNP independently
associated with HDL-C (rs2303790, p.Asp459Gly, MAF¼ 0.027;
b¼ 0.44, P¼ 3.2 10 29). For LDL-C, associations with strong
effect were detected for two probably damaging missense
changes—a rare PCSK9 variant encoding p.Arg93Cys
(rs151193009, MAF¼ 0.014; P¼ 7.9 10 32) and a LDLR
mutation encoding p.Arg257Trp (rs200990725, MAF¼ 0.001;
P¼ 3.0 10 8). Both variants appeared to be independent of
previously reported association signals. The PCSK9 p. Arg46Leu
missense variant (rs11591147) was near monomorphic in
Chinese and the GWAS index SNP (rs2479409; r2¼ 4.4 10 3)
was not associated with LDL-C in our study (P¼ 0.72). Similarly,
the LDLR p.Arg257Trp is not linked (r2¼ 1.7 10 4) with the
non-signiﬁcant index SNP (rs6511720). The two single-variant
associations identiﬁed in the current study may, by far, represent
some of the strongest effect sizes (b¼  0.64 s.d. for PCSK9
p.Arg93Cys and b¼ 0.91 for LDLR p.Arg257Trp) for any
missense variant known to associate with plasma lipid levels.
Interestingly, the association of PCSK9 p.Arg93Cys was more
prominent in PUUMA-MI (MAF¼ 0.017; b¼  0.65,
P¼ 3.2 10 25) compared with HKU-TRS (MAF¼ 0.008;
b¼  0.61, P¼ 3.7 10 8). The large discrepancy was mainly a
result of the intra-population difference, in which the risk allele
frequency of Northern Chinese is at least twice the frequency of
Southern Chinese. Such a phenomenon was also observed for
other rare variants, which underscores the need for rare variant
association analysis in a more ﬁne-scale local population.
Novel loci identiﬁed at PKD1L3 for LDL-C and PNPLA3 for TG.
Next, we sought to identify novel associations of plausibly
functional variants. Along with the 16 known loci, 2 common
nonsynonymous variants in genes/loci not previously implicated
attained exome-wide signiﬁcance (Table 1; Supplementary Fig. 2).
Regional plots of associations for these two newly identiﬁed loci
are illustrated in Fig. 1.
Here PNPLA3 p.Ile148Met (rs738409), a missense variant
known to associate with nonalcoholic fatty liver disease
(NAFLD)19, was shown to strongly inﬂuence TG level
(b¼  0.072, P¼ 4.4 10 8). As NAFLD is a condition
tightly linked to obesity and type 2 diabetes mellitus (T2DM)20,
we looked for factors that might confound the observed
association. Particularly, the HKU-TRS cohort was
overrepresented with T2DM patients relative to the general
population. We therefore stratiﬁed the sample by T2DM status
and tested if this enrichment contributed to the TG-lowering
effect. Although stronger association was observed in T2DM
cases (N¼ 3,366; b¼  0.114, P¼ 8.4 10 6) versus controls
(N¼ 1,775; b¼  0.067, P¼ 0.032), no signiﬁcant interaction
between the additive effect and T2DM was detected (P¼ 0.27).
The effect size observed in the non-T2DM group was very
similar to PUUMA-MI (b¼  0.058, P¼ 7.3 10 4), where no
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enrichment of T2DM cases was observed. Likewise, association of
PNPLA3 remained signiﬁcant (conditional P¼ 1.9 10 5 in
HKU-TRS) after adjusting for body mass index, demonstrating a
novel association independent of potential confounding factors.
The second strongest novel association mapped to a LD block
encompassing the known locus of haptoglobin-related protein
(HPR) at 16q22.2. Carriers of the PKD1L3minor allele (rs7185272,
encoding p.Thr429Ser) had signiﬁcantly lower LDL-C (P¼ 5.4
 10 8) and TC levels (P¼ 2.5 10 7). This coding variant is
not in LD with the GWAS SNP at nearby HPR (rs2000999,
r2¼ 0.027; PLDL-C¼ 1.1 10 3, PTC¼ 1.9 10 3), implying an
independent signal of association (Supplementary Data 1).
Another probably damaging, missense variant, rs1559401 encoding
PKD1L3 p.His571Gln, is indeed in complete LD with PKD1L3
p.Thr429Ser and had indistinguishable effect sizes on both lipid
traits (PLDL-C¼ 5.9 10 8; PTC¼ 2.1 10 7). We further
characterized the novel LDL-C lead SNP (rs7185272) by examining
its association in other data sets. In silico look up in the
largest publically available GWAS analyses of GLGC4 and
CardioGRAM21 revealed equally strong associations with LDL-C
(P¼ 2.8 10 9) and TC (P¼ 3.2 10 10) and slight though
insigniﬁcant decrease in CAD risk (P¼ 0.058).
Gene-based test identiﬁed TEAD2 as new HDL-associated gene.
Compared with common or low frequency variants, the statistical
power of single-variant test to detect association of individual rare
variant is generally limited. To improve power for identifying
novel lipid-associated genes, we proceeded to a gene-based
association test using RAREMETAL22, to assess the aggregate
effect of rare variants across genes. Speciﬁcally, we restricted the
analysis to nonsense variants and missense variants predicted to
be damaging23. Two MAF thresholds (o1% and o5%) were
employed for the (1) unweighted combined multivariate
collapsing burden test (CMC)24 and (2) sequence kernel
association test (SKAT)25, whereas only MAFo5% threshold
was considered for the (3) variable-threshold test (VT)26.
Three known genes—CETP (PHDL-C¼ 9.0 10 35), PCSK9
(PLDL-C¼ 1.4 10 34; PTC¼ 5.1 10 27) and APOE
(PLDL-C¼ 2.2 10 34; PTC¼ 2.0 10 12)—exhibited strong
Table 1 | Variants independently associated with blood lipids at exome-wide signiﬁcance (Po2.69 10 7).
Locus SNPs Annotation Position Alleles* Trait(s) PUUMA-MI (N¼ 7,452) HKU-TRS (N¼5,233) Combined (N¼ 12,685)
EAF (%)w Effect (s.e.)z P EAF (%) Effect (s.e.) P EAF (%) Effect (s.e.) P
Novel associations at newly identiﬁed loci
PKD1L3 rs7185272 p.Thr429Ser 16:72013797 G/C LDL-C 76.0 0.07 (0.02) 6.4 104 71.1 0.09 (0.02) 1.4 10 5 74.0 0.08 (0.01) 5.4 10 8
TC 0.06 (0.02) 1.5 10 3 0.09 (0.02) 2.7 10 5 0.07 (0.01) 2.5 10 7
PNPLA3 rs738409 p.Ile148Met 22:44324727 C/G TG 36.5 0.06 (0.02) 7.3 104 37.1 0.09 (0.02) 6.9 106 36.7 0.07 (0.01) 4.4 10 8
Asian-speciﬁc associations at known loci
PCSK9 rs151193009 p.Arg93Cys 1:55509585 C/T LDL-C 1.7 0.65 (0.06) 3.2 10 25 0.8 0.61 (0.11) 3.7 108 1.3 0.64 (0.05) 7.9 10 32
TC 0.58 (0.06) 2.0 10 20 0.50 (0.11) 4.0 106 0.56 (0.05) 5.1 10 25
CETP rs2303790 p.Asp459Gly 16:5701729 A/G HDL-C 2.3 0.36 (0.05) 3.3 10 11 3.2 0.53 (0.06) 1.5 10 20 2.7 0.44 (0.04) 3.2 10 29
LDLR rs200990725 p.Arg257Trp 19:11217315 C/T LDL-C 0.03 1.43 (0.45) 1.5 10 3 0.3 0.83 (0.18) 2.6 106 0.1 0.91 (0.17) 3.0 10 8
Other independent associations at known loci
APOB rs13306194 p.Arg532Trp 2:21252534 G/A LDL-C 11.9 0.13 (0.03) 7.5 108 14.2 0.13 (0.03) 3.6 106 12.8 0.13 (0.02) 1.2 10 12
TC 0.12 (0.03) 1.0 108 0.14 (0.03) 1.2 106 0.13 (0.02) 6.0 10 12
APOA5y rs10466588 Intergenic 11:116610249 A/G TG 14.2 0.08 (0.02) 4.4 104 10.3 0.07 (0.03) 0.036 12.6 0.08 (0.02) 4.7 10 5
HDL-C 0.09 (0.02) 1.7 104 0.03 (0.03) 0.321 0.07 (0.02) 2.9 10 4
APOA5 rs2075291 p.Gly185Cys 11:116661392 C/A HDL-C 6.0 0.32 (0.03) 8.1 10 21 6.1 0.27 (0.04) 1.4 10 10 6.0 0.30 (0.03) 1.2 10 29
DOCK6 rs737337 p.Thr712Thr 19:11347493 T/C TC 29.2 0.10 (0.02) 5.5 108 24.6 0.07 (0.02) 2.3 10 3 27.3 0.09 (0.01) 7.5 10 10
APOE rs445925 Intergenic 19:45415640 G/A TC 0.26 (0.03) 6.0 10 18 0.20 (0.03) 4.8 10 10 0.23 (0.02) 4.1 10 26
APOE rs769449 Intronic 19:45410002 G/A HDL-C 8.5 0.18 (0.03) 5.2 10 10 7.6 0.08 (0.04) 0.026 8.1 0.14 (0.02) 3.8 10 10
EAF, Effect allele frequency; HDL-C, high-density lipoprotein cholesterol; HKU-TRS, Hong Kong Theme-based Research Scheme; LDL-C, low-density lipoprotein cholesterol; PUUMA-MI, Peking University
Health Science Center and the University of Michigan Medical School study of Myocardial Infarction; SNP, single nucleotide polymorphism; TC, total cholesterol; TG, triglyceride.
For SNPs associated with more than one lipid traits, association results were listed ﬁrst with primary trait, followed by secondary trait(s).
*Reference/alternative effect alleles with respect to human reference genome hg19.
wEAFs, in percentage, are shown for PUUMA-MI, HKU-TRS and the combined meta-analysis.
zEffect sizes with respect to the effect allele are presented in s.d.
ySNP with signiﬁcant association after conditioning on the known variant. For results of conditional analysis, see Supplementary Data 1.
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Figure 1 | Regional plots of two newly discovered exome-wide signiﬁcant associations. (a) PKD1L3 rs7185272 with LDL-C and (b) PNPLA3 rs738409
with TG. SNPs are coloured on the basis of their pairwise LD values (r2) with the top SNP (purple), which has the smallest P value in the region. Pairwise LD
and the ﬁne-scale recombination rate (light blue line) were estimated based on 1000 Genomes project (March 2012) ASN genotypes. SNPs not present in
the reference panel are coloured in grey. Genes are presented by blue lines with arrows indicating the direction of transcription and rectangles as exons in
the bottom panel.
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association in gene-level tests with HDL-C, LDL-C and/or
TC (Table 2). Except APOE, the gene-based P values
exceeded the minimal P value among all single-variant tests;
however, the associations were largely attenuated (P40.01)
while conditioning on the most signiﬁcant missense variant,
indicating that the signals were largely driven by a single
coding SNP.
More importantly, via CMC burden test, we identiﬁed a
signiﬁcant gene-based association with HDL-C at a novel gene,
TEAD2 (b¼ 1.11, P¼ 1.9 10 7). Though two rare, missense
variants (rs142665148, encoding p.Asp12Asn, MAC¼ 1 and
rs139131757, encoding p.Ala266Val, MAF¼ 0.08%) predicted
to be damaging were included in the TEAD2 gene set, the gene-
based association was mainly driven by the near exome-wide
signiﬁcant TEAD2 p.Asp12Asn SNP (b¼ 1.11, P¼ 3.8 10 7).
This missense variant was consistently found to increase HDL-C
levels in both PUUMA-MI (b¼ 1.16, P¼ 9.7 10 3) and
HKU-TRS (b¼ 1.09, P¼ 1.2 10 5). Another singleton
missense SNP (TEAD2 p.Ala266Val) also showed a consistent,
though non-signiﬁcant, HDL-C-increasing effect (b¼ 1.15,
P¼ 0.25).
Exome-wide signiﬁcant variants were associated with CAD. We
further explored the relationship between the lipid-associated loci
and cardiovascular disease in the Chinese population. Specially,
we tested whether the newly identiﬁed protein-altering variants
showing independent associations with lipid traits also inﬂuenced
CAD risk (Table 3). Among the seven variants tested, ﬁve SNPs
showed a consistent direction of effect between lipid traits and
CAD (Po0.05). In particular, the (or near) Asian-speciﬁc var-
iants associated with LDL-C were also strongly associated with
CAD. The LDL-decreasing PCSK9 R93C (OR¼ 0.48, P¼ 3.8
 10 7) and APOB R532W (OR¼ 0.85, P¼ 2.9 10 4)
signiﬁcantly protected against CAD, whereas the risk for CAD
was 3.66 times higher for subjects carrying the LDL-increasing
LDLR R257W allele (P¼ 1.1 10 4). Compared with the
common variants in the same region, these rare variants
conferred much larger protective or damaging effects to CAD. In
fact, we observed a strong positive correlation between the
strengths of effect on plasma lipid levels and CAD risk (Fig. 2),
highlighting the clinical relevance of rare variants with large effect
in personalized medicine.
Discussion
This study is the ﬁrst Asian exome-wide association analysis on
blood lipid levels. By genotyping 12,685 Chinese individuals using
a custom exome array, we identiﬁed signiﬁcant association at 19
loci. Three of these loci harbour lipid-associated missense
variants, implicating three novel genes—PNPLA3, PKD1L3 and
TEAD2—not previously described. For the other 16 known loci,
we not only conﬁrmed the association signals of known GWAS
hits, but also identiﬁed novel independent associations and, above
all, revealed 3 Asian-speciﬁc associations involving rare non-
synonymous changes. This has important implications in study
design, such that, by examining the less studied non-European
populations, novel associations can be found even with a
relatively small sample size.
A major ﬁnding of our current study is the discovery of three
novel lipid-associated loci. The probably damaging, missense
variant encoding PNPLA3 p.Ile148Met, a TG lipase, was
previously demonstrated to show strong association with
NAFLD27–29. NAFLD refers to a wide spectrum of chronic liver
disorders, ranging from hepatic steatosis to nonalcoholic
steatohepatitis. It is characterized by increased hepatic fat
content and hepatic TG level, and is tightly linked with
signatures of cardiovascular diseases such as obesity, insulin
resistance and T2DM30. The nonsynonymous change was
demonstrated to reduce TG-rich very low density lipoprotein
efﬂux, limit substrate-binding to the nearby catalytic residue and
thereby impair hydrolase activity31,32. While PNPLA3 has been
Table 2 | Genes signiﬁcantly associated with lipid traits (Po8.43 10 7) in gene-based association test.
Gene Number of variants CMAF(%) Trait Best gene-based test* Effectw P
CETP 3 3.44 HDL-C SKATo5% 0.285 9.0 10 35
PCSK9 7 1.86 LDL-C SKATo5% 0.472 1.4 10 34
TC SKATo5% 0.414 5.2 10 27
APOE 3 3.74 LDL-C SKATo5% 0.408 2.2 10 34
TC burdeno5% 0.237 2.0 10 12
TEAD2 2 0.09 HDL-C burdeno1% 1.112 1.9 10 7
CMAF, cumulative minor allele frequency of all damaging variants included in the gene-based test, which gave the best P value; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; TC, total cholesterol.
*Gene-based tests (SKAT, VT or burden) for damaging and missense variants with o5% or o1% minor allele frequency.
wEffect of gene-based test is estimated from burden test (CMC) of the corresponding MAF cut-off threshold.
Table 3 | CAD case–control association analysis for all protein-altering variants with independent association.
Locus SNPs Alleles Trait(s) Annotation Freq PUUMA-MI (1,462 casesþ5,983
controls)
HKU-TRS (2,372 casesþ
3,388 controls)
Combined (3,834 casesþ9,371
controls)
(%) OR (95%CI) P OR (95%CI) P OR (95%CI) P
APOA5 rs2075291 C/A HDL-C p.Gly185Cys 6.0 1.07 (0.89–1.29) 0.47 1.25 (1.06–1.46) 7.6 10 3 1.17 (1.03–1.32) 0.013
CETP rs2303790 A/G HDL-C p.Asp459Gly 2.7 0.98 (0.72–1.32) 0.89 0.96 (0.77–1.20) 0.74 0.97 (0.81–1.16) 0.73
LDLR rs200990725 C/T LDLC p.Arg257Trp 0.1 12.12 (1.46–100.33) 0.052 3.22 (1.62–6.41) 8.8 10 4 3.66 (1.90–7.04) 1.1 104
PCSK9 rs151193009 C/T LDL-C, TC p.Arg93Cys 1.3 0.48 (0.34–0.66) 2.1 10 4 0.47 (0.28–0.78) 3.7 10 3 0.48 (0.36–0.63) 3.8 10 7
APOB rs13306194 G/A LDL-C, TC p.Arg532Trp 12.8 0.82 (0.71–0.93) 4.8 10 3 0.87 (0.77–0.97) 0.013 0.85 (0.78–0.93) 2.9 10 4
PKD1L3 rs7185272 G/C LDL-C, TC p.Thr429Ser 76 1.00 (0.91–1.12) 0.89 1.10 (1.01–1.20) 0.029 1.05 (0.99–1.12) 0.11
PNPLA3 rs738409 C/G TG p.Ile148Met 36.5 0.96 (0.88–1.05) 0.40 0.90 (0.83–0.97) 8.8 10 3 0.93 (0.87–0.98) 0.011
CAD, coronary artery disease; CI, conﬁdence interval; HDL-C, high-density lipoprotein cholesterol; HKU-TRS, Hong Kong Theme-based Research Scheme; LDL-C, low-density lipoprotein cholesterol; OR,
odds ratio; PUUMA-MI, Peking University Health Science Center and the University of Michigan Medical School study of Myocardial Infarction; SNP, single nucleotide polymorphism; TC, total cholesterol;
TG, triglyceride.
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the most robustly replicated locus for NAFLD20, its association
with plasma TG levels remains inconclusive27,33,34. No signiﬁcant
association was reported in population-based studies; however,
the minor allele G (encoding methionine) was associated with
lower TG levels in extremely obese individuals and NAFLD
patients35–37. Although these studies have shown suggestive
association with lipid variation, our current study was ﬁrst to
demonstrate a genome-wide signiﬁcant association with TG.
Multiple lines of evidence from animal studies suggest that the
catalytic inactivation of PNPLA3 can be exacerbated by
overexpressing p.Ile148Met under dietary conditions, which
expose the liver to high levels of insulin33. Moreover, insulin
increased PNPLA3 transcription through LXR-mediated
activation of SREBP-1c36, in line with the increased PNPLA3
mRNA levels observed in obese, insulin-resistant animals38.
These observations may provide an explanation for the slightly
stronger effect of PNPLA3 p.Ile148Met with TG in the T2DM
patients observed in HKU-TRS.
PKD1L3, encoding an ion channel of the polycystic kidney
disease-like family, is located at B100 kb away from a known
LDL-cholesterol locus of haptoglobin-related protein (HPR)39.
Although associated variants in both genes increase levels of
LDL-C and TC, we have demonstrated in our study that their
associations are highly independent. Besides the probably
damaging TC lead SNP, its LD proxy (rs7185272), also the lead
SNP for LDL-C, maps to a region with transcriptional
factor-binding signals for TCF7L2 and FOXA2/FOXA1 in the
ENCODE Consortium ChIP-seq data40. TCF7L2 is a well-known
type 2 DM gene affecting both fasting glucose and fasting insulin
levels41–43. Likewise, FOXA2 regulates expression of genes
essential for maintaining glucose homeostasis41,44. Indeed,
PKD1L3 was implicated as a putative sour taste receptor39 and
its expression is most abundant in liver45. It is tempting to
speculate that PKD1L3 is directly involved in glucose and lipid
metabolism. The rs7185272 variation might disrupt binding of
TCF7L2 or FOXA2, perturbing the expression of PKD1L3 and the
regulation of plasma LDL-C levels.
TEAD2, also known as transcriptional enhancer factor 4
(TEF-4), was identiﬁed as a HDL-associated gene through gene-
based burden test. It is involved in the pathway of peroxisome
proliferator-activated receptor (PPARa) regulation on lipid
metabolism, according to the Reactome database46. TEF-4 also
functions as a transcription factor for CTP:phosphocholine
cytidylyltransferase a, which is involved in biosynthesis of
phospholipid. Concentration of phospholipid, being the integral
component of the hydrophilic coat of HDL-C47, has been
suggested to correlate with HDL concentration by possibly
modulating the cellular cholesterol efﬂux48.
Consistent with other ﬁne-mapping and exome-wide genetic
analyses18,49, we detected multiple independent association signals
contributed by missense changes in known lipid-associated genes.
Specially, we identiﬁed associations of two missense changes
(APOB R532W and APOA5 G185S) with very low frequency in
non-Asian populations, as well as three Asian-speciﬁc variants
(CETP D459G, PSCK9 R93C and LDLR R257W). In line with their
large effects on lipid levels, all of these population-speciﬁc rare
variants that inﬂuence LDL-C have signiﬁcantly large impact on
CAD risk. The 50% reduction in CAD risk for PCSK9 and the
threefold increase for LDLR rare variants are indeed
unprecedented in GWAS of such a complex disorder. Further
work is required to validate these associations in a large-scale study
of an Asian cohort and to determine the causal effect.
One of the potential limitations of our study was that the
coverage of rare variants on the exome array was suboptimal in
the Chinese population. While most of the rare functional
variants are private to speciﬁc populations, under-representation
of the causative rare variants might limit statistical power,
particularly for gene-based burden tests. Exome or whole genome
sequencing is therefore needed to fully characterize and capture
these population-speciﬁc variants. We attempted to ameliorate
this deﬁciency by adding 30,368 additional coding variants to the
array, increasing the number of polymorphic coding variants
(77,073 and 90,486 in HKU-TRS and PUUMA-MI, respectively)
to approach the number observed in Europeans (80,137 in
HUNT-MI).
In summary, missense variants of three novel loci—PNPLA3,
PKD1L3 and TEAD2—showed strong evidence of association
with blood lipid levels, alongside with three Asian-speciﬁc
association signals in known loci (CETP, PSCK9 and LDLR).
Understanding the genetic architecture of how these deleterious
rare and regulatory common variants together affect disease risk
could provide more insights into the causal mechanisms, and also
facilitate the translation of these genetic ﬁndings to drug
discovery and personalized medicine.
Methods
Subjects and phenotypes. Our study comprised two main cohorts, HKU-TRS
and PUUMA-MI, with a total of 12,685 study participants of Chinese ancestry
genotyped and passed quality control. Study protocols were approved by the
institutional review boards of all institutions involved in the study and written
informed consent was obtained from all study participants.
HKU-TRS. We genotyped 6,048 Southern Chinese subjects recruited from the
Chinese CAD Cohort of the Queen Mary Hospital in Hong Kong; Hong Kong
Cardiovascular Risk Factor Prevalence Study (CRISPS)50 and Hong Kong West
Diabetes Registry (HKWDR)51. Detailed descriptions of the corresponding cohorts
are provided in Supplementary Note 1.
Fasting venous blood samples were collected for DNA and laboratory-based
biochemical analyses. General physical measurements and medical and drug
histories of each subject were recorded. Plasma lipids were measured by standard
enzymatic methods50,51. LDL-C level was calculated using the Friedewald
equation52 or by direct enzymatic colorimetric test if TG was 44.5mmol l 1.
Extreme lipid levels (44 s.d. from the mean) were set as missing to avoid false
positive ﬁndings due to outliers. For the quantitative blood lipids analyses, we
included only 5,233 subjects who were not taking any lipid-lowering drug or those
with their pre-treatment lipid levels available. Clinical characteristics of subjects
involved in the lipid association analysis are shown in Supplementary Table 9.
To evaluate if the lipid-associated loci also inﬂuence CAD, 2,372 CAD cases and
3,388 non-CAD controls were included in the data set (Supplementary Table 10).
CAD cases were deﬁned as having coronary artery revascularization interventions
(including percutaneous coronary intervention and/or coronary artery bypass graft
surgery); or those who had been diagnosed with MI; or those with stenosis of
450% in one or more of the major epicardial coronary arteries by angiogram.
Subjects who had no documented history or angiogram evidence of CAD were
deﬁned as non-CAD controls. Written informed consents were obtained from all
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Figure 2 | Comparison of effect sizes (b) between CAD and LDL-C
(square) as well as TG (triangle) for protein-altering variants with
independent association. Five missense variants denoted in Table 3 are
illustrated. Points are coloured by the signiﬁcance of association with CAD.
Pearson’s correlation coefﬁcient (r) and line of best ﬁt are shown.
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subjects, and the study protocol was approved by the Institutional Review Board of
the University of Hong Kong/Hospital Authority Hong Kong West Cluster.
PUUMA-MI. PUUMA-MI is a large-scale project designed to study
cardiovascular disease and related traits, including MI and plasma lipid levels, in
China. Samples were collected by the Joint Institute of the PUUMA-MI. In total,
8,621 samples from 4 hospitals were collected for genotyping: 5,606 from Peking
University First Hospital, 1,209 from Peking University Third Hospital, 774 from
Beijing Shijingshan Hospital and 482 from Asia Heart Disease Hospital of Wuhan.
Fasting plasma lipid levels were measured for Peking University First Hospital-
based samples and Beijing Shijingshan cohort after overnight fasting. For samples
collected from Peking University Third Hospital, TC and TG were measured by an
enzymatic method while HDL-C and LDL-C were measured by a liquid selective
detergent method. Details of the cohort description are provided in Supplementary
Note 1 and Supplementary Table 11.
According to the 2004 American College of Cardiology/American Heart
Association guideline53, criteria for acute MI are detection of rise and/or fall of
cardiac biomarkers (preferably troponin) with at least one value above the 99th
percentile of the upper reference limit together with evidence of myocardial
ischaemia with at least one of the following: symptoms of ischaemia; ECG changes
indicative of new ischaemia (new ST-T changes or new left bundle branch block);
development of pathological Q waves in the ECG; imaging evidence of new loss of
viable myocardium or new regional wall motion abnormality. Any one of the
following criteria meets the diagnosis for prior MI: development of new
pathological Q waves with or without symptoms; imaging evidence of a region of
loss of viable myocardium that is thinned and fails to contract, in the absence of a
non-ischaemic cause. For other individuals, self-reported CAD status was collected
as well at the time of blood draw. In total, we have 550 MI cases and 5,606 non-
CAD controls from Peking University First Hospital, 876 MI cases and 333 non-
CAD controls from Peking University Third Hospital, 256 MI cases and 226 non-
CAD controls from Wuhan Asia Heart Hospital, and 774 non-CAD controls from
Beijing Shijingshan Hospital.
HUNT-MI. A total of 5,643 Norwegians were selected from the second survey of
the HUNT, including 2,349 medical-record conﬁrmed MI cases and 2,317. Details
of the Norwegian sample, genotyping and phenotypes have been described18.
Genotyping. All subjects were genotyped using the Asian Exomechip, a specially
designed exome array with a custom content of 58,317 variants on top of the stan-
dard Inﬁnium HumanExome BeadChip (Illumina, CA), which interrogated a total of
302,218 variants. Details of the Asian Exomechip design has been described in a
number of studies, including the breast cancer exome-wide association analysis on
Chineses17. In brief, the original design of the exome array includes 242,901 markers,
with the majority of over 200K coding variants identiﬁed from B12,000 sequenced
genomes and exomes of primarily European ancestry. The underrepresentation of
non-European genomes in the original design limited the coverage of low frequency
variants in Asian populations54. To allow the comprehensive genotyping across the
full allele frequency spectrum, a custom panel ofB30K nonsense/missense variants
were added based on 3 independent Asian sequencing data sets of B1,000 Chinese
samples. Integrated in the custom panel were also common variants selected for
GWAS follow-up or ﬁne mapping studies. Additional information regarding the
design is provided in Supplementary Methods. Genotype calling was performed using
GenTrain version 2.0 in GenomeStudio V2011.1 (Illumina) independently for both
cohorts, followed by cohort-speciﬁc quality control.
Data quality controls. HKU-TRS. Manual inspection of genotype clusters was ﬁrst
carried out for 455,000 variants that either (1) showed evidence of bad genotype
clustering in exome array genotyping of over 9,000 subjects by collaborators17,55, or
(2) had GenTrain scoreo0.8 or (3) had high missingness (41%). A total of 4,550
markers were removed due to poor genotype clustering. Indiviudal-level QC was
carried out with regard to duplication, gender mismatch, possible sample
contamination and biological relatedness. We further employed a variant-level QC
that removed SNPs with 42% missingness or violated Hardy–Weinberg
equilibrium (Po1 10 5), or SNPs originally designed with the purpose of
quality control. Details regarding the quality controls are given in the
Supplementary Methods. After all quality control measures, 5,233 samples and
286,795 SNPs, of which 176,149 variants were monomorphic, remained in the data
set and were subject to association analysis.
PUUMA-MI. To obtain high quality genotypes, strict criteria were applied to
ﬁlter out low quality genotypes. We undertook plate-, individual- and variant-level
checks to exclude poor quality genotype calls from the data set (Supplementary
Methods). Brieﬂy, the individual-based QC criteria for ﬁltering included a call rate
of o99%, gender mismatch, excess heterozygosity and relatedness. Variant-level
QC was performed to exclude variants with low cluster score, low call rate
(o99.9%) and those deviated from Hardy–Weinberg equilibrium (Po1 10 4).
Finally, 7,452 samples and 282,456 markers were retained after quality control.
Among the successfully genotyped markers, 129,306 are polymorphic in the
Chinese samples. To further verify marker allele assignment, we examined the
correlation between allele frequency of the PUUMA-MI Chinese samples and those
of East Asian samples from 1000 Genomes Project, and a high correlation
(r2¼ 0.98) was observed.
Phenotype transformation. For the HKU-TRS data set, log transformation was
ﬁrst performed on TG and HDL-C. Phenotypes were then deﬁned as the stan-
dardized residuals of blood lipid levels after adjustment on age, gender and two
prinicpal components computed fromB22K common SNPs (MAF45%). For the
PUUMA-MI data, blood lipid levels were transformed to rank-based inverse
normal residuals to minimize the impact of outliers and ensure normality. Age, sex,
MI status (case or control) and 10 principal components estimated from AIMs
were included as covariates in the association tests.
Meta-analysis for lipid traits. We then proceeded with meta-analyses of both
single-variant and gene-based association tests using a framework of rvtests cou-
pled with RAREMETAL. First, in each cohort, we carried out single-variant
association tests for all markers passing quality controls using rvtests (http://
zhanxw.github.io/rvtests/). The computed score test statistics as well as the cor-
responding variance-covariance matrix, which summarizes the LD between mar-
kers, were shared between studies. Overall, 145,276 SNPs were polymorphic in at
least 1 individual in the combined data set.
Next, we performed single-variant meta-analysis by combining the score test
results using RAREMETAL. We restricted the analysis to SNPs that were
polymorphic in both studies and had at least 20 minor alleles in the combined data
set (MAC4¼ 20). Exome-wide signiﬁcance threshold was deﬁned as 2.69 10 7,
which accounted for multiple testing of 65,671 SNPs passing the ﬁltering criteria
(see next section). The test statistics, as visualized in a quantile–quantile plot,
appeared well-calibrated (Supplementary Fig. 10).
To leverage power for detecting low frequency and rare variants, we performed
gene-based meta-analyses, including a CMC24, VT26 and SKAT25, to evaluate their
aggregate effects in each gene. We only included loss-of-function (stopgain and
splicing) and missense variants predicted to be damaging into the gene sets.
Damaging variants were predicted by KGGseq23, which combined multiple
functional prediction methods (for example, SIFT, PolyPhen2 and CADD) to
predict pathogenic variants. Two MAF thresholds (o1% and o5%) were
employed for CMC and SKAT, whereas only MAFo5% threshold was considered
for VT. Genes with at least 20 copies of rare alleles were considered (n¼ 8,369 for
MAFo1% and 9,025 for MAFo5%). Gene-based signiﬁcance threshold was
deﬁned as Po8.43 10 7, which was equivalent to the multiple testing correction
of 59,313 effective number of tests (see next section).
Meta-analysis for CAD. Logistic regression was carried out in HKU-TRS and
PUUMA-MI to evaluate if the newly identiﬁed lipid-associated SNPs
inﬂuence CAD risk. The effect estimates and s.e. were meta-analysed using METAL
by the ﬁxed-effect inverse-variance method. Considering multiple testing of seven
association tests, we deﬁned SNPs with Po7.1 10 3 as being associated with
CAD.
Identiﬁcation of independent signals. To delineate SNPs with independent
association, we performed stepwise conditional analysis using the known lipid-
associated variants within 500 kb of the lead SNPs as covariates by RAREMETAL.
For each locus, SNPs with conditional P values reaching exome-wide signiﬁcance
(Po2.69 10 7) were considered as having independent association and the lead
SNP showing strongest evidence of independent association was later included in
the regression model as a covariate. The process was repeated until no variant
reached exome-wide signiﬁcance after adjustment.
Estimating the effective number of independent tests. While the 4 blood lipid
traits are highly correlated and there existed LD among common and low-fre-
quency variants, traditional Bonferroni correction for multiple testing of all 262,684
correlated single-variant tests (Po1.90 10 7) was likely to be too stringent,
leading to an overcorrection of the association. To take into account of the
dependences, we estimated the effective number of independent tests (Me) for both
phenotypes and genotypes using methods based on eigenvalues of the corre-
sponding correlation matrix56,57. We estimated the Me to be 3.41 for phenotypes
and 54,463 for genotypes, totalling 185,719 independent single-variant tests.
Exome-wide signiﬁcance threshold for single-variant meta-analysis was therefore
deﬁned as 2.69 10 7 (¼ 0.05/185,719). Similarly, for gene-based meta-analysis,
exome-wide signiﬁcance threshold was deﬁned as P¼ 8.43 10 7, equivalent to
multiple testing correction of 59,313D(8,369þ 9,025) 3.41 independent tests for
the 8,369 and 9,025 genes with MAF o1% and o5%, respectively.
Asian-speciﬁc variants. According to the ancestry of samples (http://www.
1000genomes.org), we divided the individuals of 1000 Genomes into three popu-
lations: Asian (CHB, CHS and JPT), European (CEU, FIN, GBR, IBS and TSI) and
African (ASW, LWK and YRI). For each population, the MAF was estimated
separately. Variants were classiﬁed as Asian-speciﬁc if they were polymorphic
(MAF40) in the Asian population but monomorphic in both the European and
African populations.
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